Proteocyte and the American Academy of Oral Medicine Announce Multi-Year Corporate Affiliate Program Agreement

Toronto, ON; January 2, 2024 – Proteocyte AI is pleased to announce a new 2-year Corporate Affiliate Program agreement with the American Academy of Oral Medicine (AAOM).

This corporate affiliate program agreement further reinforces Proteocyte’s dedication to producing a range of technological solutions for the future of precision medicine, including STRATICYTE™, its first commercial product that predicts a patient’s risk of developing oral cancer.

“The collaborate program agreement with AAOM is an example of Proteocyte’s dedication to supporting education and awareness initiatives around oral health”, says Proteocyte CEO Mark Hammar. “Teaming up with the AAOM also demonstrates our commitment to providing broader access to new innovations, like the advanced STRATICYTE™ prognostic lab test and its advancement of the management of oral pre-cancer patients.”

“We are very excited to announce our new collaboration with Proteocyte AI”, states Dr. Vidya Sankar, AAOM President and Associate Professor and Division Director for Oral Medicine at Tufts University School of Dental Medicine. “We look forward to working with this innovative company whose initiatives are aligned with AAOM’s mission to advance excellence in patient care, education and increasing professional and public awareness of the field of oral medicine”.

About AAOM:

The American Academy of Oral Medicine (AAOM), founded in 1945, is the membership organization representing the discipline of Oral Medicine. The membership provides care to thousands of our nation’s youth and adults whose underlying medical condition affects oral health and the delivery of dental care.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Proteocyte management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.